DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/h6pm58/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions.
The pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. The two drug makers will combine and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline. Revenues of major pharma companies are broke out by these therapeutic areas in the report, Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023.
Novartis has about 1/3 of its pharmaceutical revenues coming from oncology products. Thus it certainly makes sense to build that area, according to Kalorama's report. Novartis is currently number 2 in the world for cancer therapies behind Roche. The firm does not think that Novartis rises in market share from the deal, but it does believe it will certainly strengthen its position and maintain its wide distance from the 3rd competitor in the market.
Although Kalorama also thinks the move benefits Glaxo Smith Kline, there could be less advantages for the company in the deal than for Novartis.
Novartis will keep influenza vaccines, as part of the deal. This could work out to be highly beneficial, vaccines is a competitive area. The positions of companies do shift somewhat from year to year with vacillations in flu vaccines and other specific products, although for the past few years, Glaxo has led the market and Novartis has trailed at a distance. Furthermore, in pediatric vaccines GSK is also a major contributor and leader and solidifying this position is good but is not really helpful in the overall picture.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 estimates current sales for major pharmaceutical companies, breaks out revenue by therapeutic area and discusses general trends in the industry. Market watchers can use the report to understand developments in greater context than news media can provide.
For each company, the report provides:
- R&D Spending 2007-2013
- Geographic Breakout of Revenues
- Performance of Specific Products
- Performance by Drug Category
- Late-Stage Pipeline
- Projections of Revenues to 2023
Top 25 Companies Mentioned
- Abbvie, inc.
- Amgen, inc.
- Astra Zeneca plc
- Baxter international
- Bayer AG
- Boehringer Ingelheim gmbh
- Bristol-myers Squibb Company
- Daiichi Sankyo
- Eli Lilly and Company
- Gilead Sciences
- Glaxosmithkline PLC
- Johnson & johnson
- Merck & Co., inc.
- Merck KGAA
- Novartis AG
- Novo nordisk
- Otsuka Pharmaceutical
- Pfizer, inc.
- Roche ltd.
- Takeda Pharmaceutical co., LTD
- Teva Pharmaceutical Industries, Ltd.
For more information visit http://www.researchandmarkets.com/research/h6pm58/top_25